Rhythms in human bone marrow and blood cells

REFERENCES

• Buchi K.N., Moore J.G., Hrushesky W.J.M., Sothern R.B., Rubin N.H. Circadian Rhythm of Cellular Proliferation in the Human Rectal Mucosa. Gastroenterology 1991; 101: 410–415
   PubMed Web of Science ®Google Scholar
• Fisher L.B. The Diurnal Mitotic Rhythm in the Human Epidermis. Br. J. Dermatol. 1968; 60: 75–80
   Google Scholar
• Scheving L.E. Mitotic Activity in the Human Epidermis. Anat. Rec. 1959; 135: 7–19
   PubMedGoogle Scholar
• Spivak J.L. Normal Hematopoiesis. Appleton-Century-Crofts, Norwalk 1984
   Google Scholar
• Nathan D.G. Stem Cells and Hematopoiesis. Oxford University Press, Oxford 1987
   Google Scholar
• Gordon M.Y., Barrett A.J., Gordon-Smith E.C. Bone Marrow Disorders. Blackwell Scientific, Oxford 1985
   Google Scholar
• Lewis A.D., Hayes J.D., Wolf C.R. Glutathione and Glutathione-Dependent Enzymes in Ovarian Adenocarcinoma Cell Lines Derived from a Patient Before and After the Onset of Drug Resistance: Intrinsic Differences and Cell Cycle Effects. Carcinogenesis 1988; 9: 1283–1287
   PubMed Web of Science ®Google Scholar
• Pollak M.N., Brennan L.V., Antman K., Elias A., Cannistra S.A., Socinsky M.A., Schnipper L.E., Frei E., Griffin J.D. Recombinant GM-CSF in Myelosuppression of Chemotherapy. N. Engl. J. Med. 1989; 320: 253–254
   PubMedGoogle Scholar
• Nathan D.G. Hematologic Diseases. W. B. Saunders, Philadelphia 1988
   Google Scholar
• Gale R.P. Myelosuppressive Effects of Antineoplastic Chemotherapy. Marcel Dekker, Inc., New York 1988
   Google Scholar
• Evans W.E. Clinical Pharmacodynamics of Anticancer Drugs: A Basis for Extending the Concept of Dose-Intensity. Blut 1988; 56: 241–248
   PubMedGoogle Scholar
• Huinink W.T., Moiseyenko V., Glimelius B., Kjaer M., Starkhammar H., Richel D., Smaaland R., Gruia G., Mourier A., Sibaud D. A Randomized Phase II Multicenter Trial of Irinotecan (CPT-11) Using Different Schedules in Patients with Metastatic Colorectal Cancer. Proc. ASCO 2000; 19: 245a
   Google Scholar
• Hryniuk W., Figueredo A., Goodyear M. Applicarions of Dose Intensity to Problems in Chemotherapy of Breast and Colorectal Cancer. Semin. Oncol. 1987; 14: 3–11
   PubMed Web of Science ®Google Scholar
• Laerum O.D., Smaaland R., Sletvold O. Rhythms in Blood and Bone Marrow: Potential Therapeutic Implications. Marcel Dekker, Inc., New York 1989
   Google Scholar
• Wintrobe M.M. Clinical Hematology. Lead and Febiger, Philadelphia, PA 1981
   Google Scholar
• Dethmers J.K., Meister A. Glutathione Export by Human Lymphoid Cells: Depletion of Glutathione by Inhibition of Its Synthesis Decreases Export and Increases Sensitivity to Irradiation. Proc. Natl Acad. Sci. USA 1981; 78: 7492–7496
   PubMed Web of Science ®Google Scholar
• Friedman H.S., Colvin O.M., Griffith O.W., Lippitz B., Elion G.B., Schold S.C., Hilton J., Bigner D.D. Increased Melphalan Activity in Intracranial Human Medulloblstoma and Glioma Xenografts Following Buthionine Sulfoximine-Mediated Gluthatione Depletion. J. Natl Cancer Inst. 1989; 81: 524–527
   PubMedGoogle Scholar
• Lee F.Y.F., Allalunis-Turner M.J., Siemann D.W. Depletion of Tumor Versus Normal Tissue Glutathione by Buthionine Sulfoximine. Br. J. Cancer 1987; 56: 33–38
   PubMed Web of Science ®Google Scholar
• Lee F.Y.F., Siemann D.W., Sutherland R.M. Changes in Intracellular GSH Content During Adriamycin Treatment in Human Ovarian Cancer—A Possible Indicator of Chemosensitivity. Br. J. Cancer 1989; 60: 291–298
   PubMedGoogle Scholar
• Lee F.Y.F., Siemann D.W., Allalunis-Turner M.J., Keng P.C. Glutathione Contents in Human and Rodent Tumor Cells in Various Phases of the Cell Cycle. Cancer Res. 1988; 48: 3661–3665
   PubMedGoogle Scholar
• Beck W.S. Hematopoiesis. MIT Press, Cambridge 1991
   Google Scholar
• Cardoso S.S., Scheving L.E., Halberg F. Mortality of Mice as Influenced by the Hour of Day of Drug (ara-C) Administration. Pharmacologist 1970; 12: 302
   Google Scholar
• Haus E., Halberg F., Scheving L.E., Pauly J.E., Cardoso S., Kuhl J.F.W., Sothern R.B., Shiotsuka R.N., Hwang D.S. Increased Tolerance of Leukemic Mice to Arabinosyl Cytosine with Schedule Adjusted to Circadian System. Science 1972; 177: 80–82
   PubMed Web of Science ®Google Scholar
• Kühl J.F.K., Haus E., Halberg F., Scheving L.E., Pauly J.E., Cardoso S.S., Rosene G. Experimental Chronotherapy with ara-C; Comparison of Murine ara-C Tolerance on Differently Timed Treatment Schedules. Chronobiologia 1974; 1: 316–317
   Google Scholar
• Scheving L.E., Haus E., Kühl J.F.W., Pauly J.E., Halberg F., Cardoso S.S. Close Reproduction by Different Laboratories of Characteristics of Circadian Rhythms in 1-β-d-Arabinofuranosylcytosine Tolerance by Mice. Cancer Res. 1976; 36: 1133–1137
   PubMed Web of Science ®Google Scholar
• Scheving L.E., Pauly J.E., Tsai T.H., Scheving L.A. Chronobiology of Cell Proliferation. Implication for Cancer Chemotherapy. Springer-Verlag, Berlin 1983
   Google Scholar
• Scheving L.E., Burns E.R., Halberg F., Pauly J.E. Combined Chronochemotherapy of L1210 Leukemic Mice Using 1-β-d-Arabino-furanosylcytosine, Cyclophosphamide, Vincristine, Methyl-Prednisolone, and Cis-Platinum. Chronobiologia 1980; 17: 33–40
   Google Scholar
• Scheving L.E. Chronobiology of Cell Proliferation. Springer-Verlag, New York 1983
   Google Scholar
• Hrushesky W.J.M. Circadian Timing of Cancer Chemotherapy. Science 1985; 228: 73–75
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., Roemeling R.v., Sothern R.B. Preclinical and Clinical Cancer Chronotherapy. Wright, London 1989
   Google Scholar
• Kerr D.J., Lewis C., O'Neill B., Lawson N., Blackie R.G., Newell D.R., Boxall F., Cox J., Rankin E.M., Kaye S.B. The Myelotoxicity of Carboplatin Is Influenced by the Time of Its Administration. Hematol. Oncol. 1990; 8: 59–63
   PubMedGoogle Scholar
• Rivard G.E., Infante-Rivard C., Hoyoux C., Champagne J. Maintenance Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Better in the Evening. Lancet 1985; 2: 1264–1266
   PubMed Web of Science ®Google Scholar
• Rivard G.E., Infante-Rivard C., Dresse M.-F., Leclerc J.-M., Champagne J. Circadian Time-Dependent Response of Childhood Lymphoblastic Leukemia to Chemo-therapy: A Long-Term Follow-up Study of Survival. Chronobiol. Int. 1993; 10: 201–204
   PubMed Web of Science ®Google Scholar
• Nelson W., Tong Y., Lee J.K, Hazberg F. Methods for Cosinor Rhytmometry. Chronobiologia 1979; 6: 305–323
   PubMedGoogle Scholar
• Smaaland R., Abrahamsen J.F., Svardal A.M., Lote K., Ueland P.M. DNA Cell Cycle Distribution and Glutathione (GSH) Content According to Circadian Stage in Bone Marrow of Cancer Patients. Br. J. Cancer 1992; 66: 39–45
   PubMed Web of Science ®Google Scholar
• Biaglow J.E., Varnes M.E., Clark E.P., Epp E.P. The Role of Thiols in Cellular Response to Radiation and Drugs. Radiat. Res. 1983; 94: 437–455
   Google Scholar
• Bump E.A., Yu N.Y., Brown J.M. The Use of Drugs Which Deplete Intracellular Glutathione in Hypoxic Cell Radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 439–442
   PubMed Web of Science ®Google Scholar
• Hamilton T.C., Winker M.A., Louie K.G., Batist G., Behrens B.C., Tsuruo T., Grotzinger K.R., McKoy W.M., Young R.C., Ozols R.F. Augmentation of Adriamycin, Melphalan and Cisplatin Cytotoxicity in Drug-Resistant and -Sensitive Human Ovarian Carcinoma Cell Lines by Buthionine Sulfoximine Mediated Glutathione Depletion. Biochem. Pharmacol. 1985; 34: 2583–2586
   PubMed Web of Science ®Google Scholar
• Ono K., Shrieve D.C. Enhancement of EMT6/SF Tumor Cell Killing by Mitomycin C and Cyclophosphamide Following In Vivo Administration of Buthionine Sulfoximine. Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 1175–1178
   PubMedGoogle Scholar
• Tsutsui K., Komuro C., Ono K., Nishidai T., Shibamato Y., Takahashi M., Abe M. Chemosenzitation by Buthionine Sulfoximine In Vivo. Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 1183–1186
   PubMed Web of Science ®Google Scholar
• Dusre L., Mimnaugh E.G., Myers C.E., Sinha B.K. Potentiation of Doxorubicin Cytotoxicity by Buthionine Sulfoximine in Multidrug-Resistant Human Breast Tumor Cells. Cancer Res. 1989; 49: 511–515
   PubMed Web of Science ®Google Scholar
• Green J.A., Vistica D.T., Young R.C., Hamilton T.C., Rogan A.M., Ozols R.F. Potentiation of Melphalan Cytotoxicity in Human Ovarian Cancer Cell Lines by Glutathione Depletion. Cancer Res. 1984; 44: 5427–5431
   PubMed Web of Science ®Google Scholar
• Smaaland R., Svardal A.M., Lote K., Ueland P.M., Laerum O.D. Glutathione Content in Human Bone Marrow and Circadian Stage Relation to DNA Synthesis. J. Natl Cancer Inst. 1991; 83: 1092–1098
   PubMed Web of Science ®Google Scholar
• Bellamy W.T., Alberts D.S., Dorr R.T. Daily Variation in Non-protein Sulfhydryl Levels of Human Bone Marrow. Eur. J. Cancer Clin. Oncol. 1988; 11: 1759–1762
   Google Scholar
• Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a Cisdiaminedichloroplatinum (II)-Resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues. Cancer Res. 1987; 47: 414–418
   PubMed Web of Science ®Google Scholar
• Shaw J.P., Chou I.N. Elevation of Intracellular Glutathione Content Associated with Mitogenic Stimulation of Quiescent Fibroblasts. J. Cell. Physiol. 1986; 129: 193–198
   PubMed Web of Science ®Google Scholar
• Lasky L.C., Ascencao J., McCullough J., Zanjian E.D. Steroid Modulation of Naturally Occuring Diural Variations in Circulating Pluripotential Haemotopoietic Cells. Br. J. Haemotol. 1983; 55: 615–622
   PubMed Web of Science ®Google Scholar
• Morra L., Ponassi A., Caristo G., Bruzzi P., Zunino R., Parodi G.B., Sacchetti C. Comparison Between Diural Changes and Changes Induces by Hydrocortisone and Epinephrine in Circulating Myeloid Progenitor Cells (CFU—GM) in Man. Biomed. Pharmacother. 1984; 38: 167–170
   PubMed Web of Science ®Google Scholar
• Ross D.D., Pollack A., Akman S.A., Bachur N.R. Diurnal Variation of Circulating Human Myeloid Progenitor Cells. Exp. Hematol. 1980; 8: 954–960
   PubMed Web of Science ®Google Scholar
• Verma D.S., Fisher R., Spitzer G., Zander A.R., McCredie K.B., Dicke K.A. Diurnal Changes in Circulating Myeloid Progenitor Cells in Man. Am. J. Hematol. 1980; 9: 185–192
   PubMedGoogle Scholar
• Smaaland R., Laerum O.D., Sothern R.B., Sletvold O., Bjerknes R., Lote K. Colony-Forming Units—Granulocyte/Macrophage and DNA Synthesis of Human Bone Marrow Are Circadian Stage-Dependent and Show Covariation. Blood 1992; 79: 2281–2287
   PubMed Web of Science ®Google Scholar
• Killmann S.-Å., Cronkite E.P., Fliedner T.M., Bond V.P. Mitotic Indices of Human Bone Marrow Cells. I. Number and Cytologic Distribution of Mitosis. Blood 1962; 19: 743–750
   PubMed Web of Science ®Google Scholar
• Mauer A.M. Diurnal Variation of Proliferative Activity in the Human Bone Marrow. Blood 1965; 26: 1–7
   PubMed Web of Science ®Google Scholar
• Abrahamsen J.F., Smaaland R., Skjærven R., Laerum O.D. Flow Cytometric Measurement of DNA S-Phase in Human Bone Marrow Cells: Correcting for Peripheral Blood Contamination. Eur. J. Haematol. 1995; 56: 138–147
   Google Scholar
• Abrahamsen J.F., Lund-Johansen F., Laerum O.D., Schem B.C., Sletvold O., Smaaland R. Flow Cytometric Assessment of Peripheral Blood Contamination and Proliferative Activity of Human Bone Marrow Cell Populations. Cytometry 1995; 19: 77–85
   PubMedGoogle Scholar
• Brons P.P.T., Pennings A.H.M., Haanan C., Wessels H.M.C., Boezeman J.B.M. Simultaneous Measurement of DNA Content and Cell-Surface Immunofluorescence of Human Bone Marrow Cells Using a Single Laser Flow Cytometer. Cytometry 1990; 11: 837–844
   PubMedGoogle Scholar
• Abrahamsen J.F., Smaaland R., Sothern R.B., Laerum O.D. Variation in Cell Yield and Proliferative Activity of Positive Selected Human CD34+ Bone Marrow Cells Along the Circadian Time Scale. Eur. J. Haematol. 1998; 60: 7–15
   PubMedGoogle Scholar
• Halberg F., Sothern R.B., Roitman B., Halberg E., Benson E., Halberg F., Mayersbach H., Haus E. Agreement of Circadian Chracteristics for Total Leukocyte Counts in Different Geographic Locations. Proc. XII Int. Conf. Int. Soc. Chronobiol. 1977; 3–17
   Google Scholar
• Haus E., Lakatua D.J., Swoyer J., Sackett-Lundeen L. Chronobiology in Hematology and Immunology. Am. J. Anat. 1983; 168: 467–517
   PubMedGoogle Scholar
• Kanabrocki E.L., Sothern R.B., Scheving L.E. Reference Values for Circadian Rhythms of 98 Variables in Clinically Healthy Men in Fifth Decade of Life. Chronobiol. Int. 1990; 7: 445–461
   PubMed Web of Science ®Google Scholar
• Lévi F., Canon C., Blum J.-P., Mechkouri M., Reinberg A., Mathé G. Circadian/or Circahemidian Rhythms in Nine Lymphocyte Related Variables from Peripheral Blood of Healthy Subjects. J. Immunol. 1985; 134: 217–222
   PubMed Web of Science ®Google Scholar
• Smaaland R., Sothern R.B., Lote K., Sandberg S., Aakvaag A., Laerum O.D. Circadian Phase Relationships Between Peripheral Blood Variables and Bone Marrow Proliferative Activity in Clinical Health. In Vivo 1995; 9: 379–390
   PubMedGoogle Scholar
• Sothern R.B. Time of Day Versus Internal Circadian Timing References. J. Infus. Chemother. 1995; 5: 24–30
   PubMedGoogle Scholar
• Abrahamsen J.F., Smaaland R., Sothern R.B., Laewrum O.D. Circadian Cell Cycle Variations of Erythro- and Myelopoiesis in Man. Eur. J. Hematol. 1997; 58: 333–345
   PubMed Web of Science ®Google Scholar
• Smaaland R., Laerum O.D., Lote K., Sletvold O., Sothern R.B., Bjerknes R. DNA Synthesis in Human Bone Marrow in Circadian Stage Dependent. Blood 1991; 77: 2603–2611
   PubMed Web of Science ®Google Scholar
• Abrahamsen J.F., Smaaland R., Sandberg S., Aakvaag A., Lote K. Circadian Variation in Serum Cortisol and Circulating Neutrophils Are Markers for Circadian Variation of Bone Marrow Proliferation in Cancer Patients. Eur. J. Haematol. 1993; 50: 206–212
   PubMed Web of Science ®Google Scholar
• Focan C. Marker Rhythms for Cancer Chronotherapy. From Laboratory Animals to Human Beings. In Vivo 1995; 9: 283–298
   PubMedGoogle Scholar
• Hrushesky W.J.M., Haus E., Lakatua E., Halberg F., Langevin T., Kennedy B. Marker Rhythms for Chron-chemotherapy. S. Karger, Basel 1984; 1982–1983
   Google Scholar
• Mormont C.M., Comisso M., Langouet A.M., Massari C., Bogdan A., Marion S., Touitou Y., Jasmin C., Lévi F. Cortisol and Hematologic Circadian Rhythms in Patients with Metastatic Colorectal Cancer. Chronobiol. Int. 1996; 13: 92
   Google Scholar
• Abrahamsen J.F., Sothern R.B., Sandberg S., Aakvaag A., Laerum O.D., Smaaland R. Circadian Variations in Human Peripheral Blood on Days with and without Bone Marrow Sampling and Relation to Bone Marrow Cell Proliferation. Biol. Rhythm Res. 1999; 30: 29–53
   Google Scholar
• Lévi F., Halberg F., Nesbit M., Haus E., Levine H. Chronooncology. Williams and Wilkins, Baltimore 1981
   Google Scholar
• Focan, C. Le Rythme Nycthémeral de la Prolifération Tumorale: Aspects Expérimentaux et Cliniques: Implication pour la Chimiothérapie Oncolytique, 1985.
   Google Scholar
• Smaaland R., Lote K., Sothern R.B., Laerum O.D. DNA Synthesis and Ploidy in Non-Hodgkin's Lymphomas Demonstrate Intra-patient Variation Depending on Circadian Stage of Cell Sampling. Cancer Res. 1993; 53: 3129–3138
   PubMed Web of Science ®Google Scholar
• Voutilainen A. Über Die 24-Stunden-Rhythmik der Mitozfrequenz in Malignen Tumoren. Acta Pathol. Microbiol. Scand. 1953; 99: 1–104
   Google Scholar
• Meyn R.E., Murray D. Cell Cycle Effects of Alkylating Agents. Pergamon Press, Oxford 1986
   Google Scholar
• Bhuyan B.K., Schedit L.G., Fraser T.J. Cell Cycle Phase Specificity of Antitumor Agents. Cancer Res. 1972; 32: 398–407
   PubMed Web of Science ®Google Scholar
• Traganos F., Darzynkiewicz Z., Melamed M.R. Effects of the l-Isomer (+)-1,2-Bis(3,5-dioxopiperazine-lyl) Propane on Cell Survival and Cell Progression of Cultured Mammalian Cells. Cancer Res. 1981; 41: 4566–4576
   PubMedGoogle Scholar
• Traganos F., Staiano-Coico L., Darzynkiewicz Z., Melamed M.R. Effects of Aclacinomycin on Cell Survival and Cell Cycle Progression and Survival of Cultured Mammalian Cells. Cancer Res. 1981; 41: 2273–2278
   PubMedGoogle Scholar
• Lévi F., Blazcek I., Ferlé-Vidovic A. Circadian and Seasonal Changes in Murine Bone Marrow Colony Forming Cells Affect Tolerance for 4′Tetrahydropyranyladriamycin. Exp. Hematol. 1988; 16: 696–701
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., Märtz W.J. Chronochemotherapy of Malignant Tumors: Temporal Aspects of Antineoplastic Drug Toxicity. Berlin, Springer-Verlag 1992
   Google Scholar
• Paukovits W.R., Guigon M., Binder K.A., Hergl A., Laerum O.D., Schulte-Hermann R. Prevention of Hematotoxic Side Effects of Cytostatic Drugs in Mice by a Synthetic Hemoregulatory Peptide. Cancer Res. 1990; 50: 328–332
   PubMedGoogle Scholar
• Sothern R.B., Roitman-Johnson B. Biological Rhythms and Immune Function. Academic Press, San Diego 2001
   Google Scholar
• Sothern R.B., Roitman-Johnson B., Kanabrocki E.L., Yager J.G., Fuerstenberg R.K., Weatherbee J.A., Young M.R.I., Nemchausky B.M., Scheving L.E. Circadian Characteristics of Circulating Interleukin-6 in Men. J. Allergy Clin. Immunol. 1995; 95: 1029–1035
   PubMed Web of Science ®Google Scholar
• Young M.R.I., Matthews J.P., Kanabrocki E.L., Sothern R.B., Roitman-Johnson B., Scheving L.E. Circadian Rhythmometry of Serum Interleukin-2, Interleukin-10, Tumor Necrosis Factor-L, and Granulocyte-Macrophage Colony-Stimulating Factor in Men. Chronobiol. Int. 1995; 12: 19–27
   PubMed Web of Science ®Google Scholar
• Byron J.W. Evidence for a Beta-Adrenergic Receptor Initiating DNA Synthesis in Hemopoietic Stem Cells. Exp. Cell. Res. 1992; 71: 228–232
   Google Scholar
• Maestroni G.J.M. T-Helper-2 Lymphocytes as a Peripheral Target of Melatonin. J. Pineal Res. 1995; 18: 84–89
   PubMed Web of Science ®Google Scholar
• Haldar C., Haussler D., Gupta D. Effect of the Pineal Gland on Circadian Rhythmicity of Colony Forming Units for Granulocytes and Macrophages (CFU—GM) from Rat Bone Marrow Cell Cultures. J. Pineal Res. 1992; 12: 79–83
   PubMed Web of Science ®Google Scholar
• Haldar C., Haussler D., Gupta D. Response of CFU—GM (Colony Forming Units for Granulocytes and Macrophages) from Intact and Pinealectomized Rat Bone Marrow to Murine Recombinant Interleukin-3 (rIL-3), Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF) and Human Recombinant Erythropoietin (rEPO). Elsevier Science, Amsterdam 1992
   Google Scholar